CO-ADMINISTRATION OF OMEPRAZOLE AND EICOSAPENTAENOIC ACID OR A DERIVATIVE THEREOF

1 . A method of reducing triglycerides in a subject on omeprazole therapy, the method comprising administering to the subject a pharmaceutical composition comprising at least about 80%, by weight of all fatty acids (and/or derivatives thereof) present, ethyl eicosapentaenoate.

2 . The method of claim 1 , wherein the subject has a fasting baseline triglyceride level of about 200 mg/dl to 499 mg/dl.

3 . The method of claim 2 , wherein the reduction in triglycerides is in comparison to a second subject or second subject group having a fasting baseline triglyceride level or a mean or median fasting baseline triglyceride level of about 200 mg/dl to 499 mg/dl.

4 . The method of claim 1 , wherein the subject has a fasting baseline triglyceride level of at least 500 mg/dl.

5 . The method of claim 4 , wherein the reduction in triglycerides is in comparison to a second subject or second subject group having a fasting baseline triglyceride level or a mean or median fasting baseline triglyceride level of at least 500 mg/dl.

6 . The method of claim 1 , wherein triglycerides are reduced in the subject with no increase in an LDL-C level in the subject.

7 . The method of claim 6 , wherein the reduction in triglycerides and the no increase in LDL-C level is in comparison to baseline or to a second subject or subject group that has received omeprazole but not the ethyl eicosapentaenoate.

8 . The method of claim 1 , wherein ethyl eicosapentaenoate represents at least about 90%, by weight of all fatty acids (and/or derivatives thereof) present.

9 . The method of claim 1 , wherein docosahexaenoic acid and its esters represent no more than about 20%, by weight of all fatty acids (and/or derivatives thereof) present in the pharmaceutical composition or capsule.

10 . A method of reducing triglycerides in a subject on omeprazole therapy, the method comprising administering to the subject about 4 g per day of ethyl eicosapentaenoate.

11 . The method of claim 10 , wherein the subject has a fasting baseline triglyceride level of about 200 mg/dl to 499 mg/dl.

12 . The method of claim 11 , wherein the reduction in triglycerides is in comparison to a second subject or second subject group having a fasting baseline triglyceride level or a mean or median fasting baseline triglyceride level of about 200 mg/dl to 499 mg/dl.

13 . The method of claim 10 , wherein the subject has a fasting baseline triglyceride level of at least 500 mg/dl.

14 . The method of claim 13 , wherein the reduction in triglycerides is in comparison to a second subject or second subject group having a fasting baseline triglyceride level or a mean or median fasting baseline triglyceride level of at least 500 mg/dl.

15 . The method of claim 10 , wherein triglycerides are reduced in the subject with no increase in an LDL-C level in the subject.

16 . The method of claim 15 , wherein the reduction in triglycerides and the no increase in LDL-C level is in comparison to baseline or to a second subject or subject group that has received omeprazole but not the ethyl eicosapentaenoate.

17 . The method of claim 10 , wherein ethyl eicosapentaenoate comprises at least about 80%, by weight of all fatty acids (and/or derivatives thereof) present.

18 . The method of claim 17 , wherein ethyl eicosapentaenoate represents at least about 90%, by weight of all fatty acids (and/or derivatives thereof) present.

19 . The method of claim 10 , wherein docosahexaenoic acid and its esters represent no more than about 20%, by weight of all fatty acids (and/or derivatives thereof) present in the pharmaceutical composition or capsule.

20 . A method of reducing a risk of a cardiovascular event in a subject on omeprazole therapy, the method comprising in a subject on omeprazole therapy, the method comprising administering to the subject about 4 g per day of ethyl eicosapentaenoate.